Injectable hemostatic adjuncts in trauma: Fibrinogen and the FIinTIC study

Journal of Trauma and Acute Care Surgery

Volumn 78, Issue 6, 2015, Pages S76-S82

  Maegele, Marc ^a   Zinser, Max ^b   Schlimp, Christoph ^c,d,e   Schöchl, Herbert ^c,d   Fries, Dietmar ^a,f  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c LUDWIG BOLTZMANN INSTITUTE FOR EXPERIMENTAL AND CLINICAL TRAUMATOLOGY   (Austria)

^d GENERAL HOSPITAL KLAGENFURT   (Austria)

^e AUVA Trauma Center Salzburg   (Austria)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOGEN CONCENTRATE; TRANEXAMIC ACID; HEMOSTATIC AGENT;

BLEEDING; BLOOD CLOTTING DISORDER; BLUNT TRAUMA; CONFERENCE PAPER; CRYOPRECIPITATE; EMERGENCY HEALTH SERVICE; FIBRINOGEN BLOOD LEVEL; GLASGOW COMA SCALE; HEMOSTASIS; HUMAN; HYPOFIBRINOGENEMIA; INJURY; INJURY SCALE; INJURY SEVERITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOCYTE; BLOOD COAGULATION DISORDERS; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SHOCK, HEMORRHAGIC; WOUNDS AND INJURIES;

BLOOD COAGULATION DISORDERS; BLOOD PLATELETS; FIBRINOGEN; HEMOSTASIS; HEMOSTATICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SHOCK, HEMORRHAGIC; WOUNDS AND INJURIES;

EID: 84939426619     PISSN: 21630755     EISSN: 21630763     Source Type: Journal    
DOI: 10.1097/TA.0000000000000632     Document Type: Conference Paper

References (61)

1. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894-1904.
2. Fries D, Martini WZ. Role of fibrinogen in trauma-induced coagulopathy. Br J Anaesth. 2010;105(2):116-121.
3. Spahn D. Severe bleeding in surgical and trauma patients: the role of fibrinogen replacement therapy. Thromb Res. 2012;130(SUPPL. 2):S15-S19.
4. Sorensen B, Larsen OH, Rea C, Tang M, Foley J, Fenger-Eriksen C. Fibrinogen as a hemostatic agent. Semin Thromb Hemost. 2012;38(3):268-273.
5. Korte W. Fibrin monomer and factor XIII: a new concept for unexplanined intraoperative coagulopathy. Hamostaseologie. 2006;26:S30-S35.
6. Sorensen B, Tang M, Larsen OH, Laursen PN, Fenger-Eriksen C, Rea CJ. The role of fibrinogen: a new paradigm in the treatment of coagulopathic bleeding. Thromb Res. 2011;128(SUPPL. 1):S13-S16.
7. Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg. 1995;81(2):360-365.
8. Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levals and replacement therapy. Transfusion. 2014;54(5):1389-1405.
9. Floccard B, Rugeri L, Faure A, Saint Denis M, Boyle EM, Pequet O, Levrat A, Guillaume C, Marcotte G, Vulliez A, Hautin E, David JS, Negrier C, Allaouchiche B. Early coagulopathy in trauma patients: an on-scene and hospital admission study. Injury. 2012;43(1):26-32.
10. Kimura Y, Kimura S, Sumita S, Yamakage M. Predictors of hypofibrinogenemia in blunt trauma patients on admission. J Anesth. 2014 [Epub ahead of print].
11. Rizoli S, Nascimiento B Jr, Key N, Tien HC, Muraca S, Pinto R, Khalifa M, Plotkin A, Callum J. Disseminated intravascular coagulopathy in the first 24 hours after trauma: the association between ISTH score and anatomopathologic evidence. J Trauma. 2011;71(5 Suppl 1):S441-S447.
12. Fries D, Streif W, Haas T, Kuhbacher G. Dilutional coagulopathy, an underestimated problem? Anaesthesiol Intensivmed Notfallmed Schmerzther. 2004;39:745-750.
13. Martini WZ, Holcomb J. Acidosis and coagulopathy: the differential effects on fibrinogen synthesis and breakdown in pigs. Ann Surg. 2007;246:831-835.
14. Martini WZ. The effects of hypothermia on fibrinogen metabolism and coagulation function in swine. Metabolism. 2007;56:214-221.
15. Deras P, Villiet M, Manzanera J, Latry P, Schved JF, Capdevilla X, Charbit J. Early coagulopathy at hospital admission predicts initial or delayed fibrinogen deficit in severe trauma patients. J Trauma Acute Care Surg. 2014; 77(3):433-440.
16. Hess J, Lindell AL, Stansbury LG, Dutton RP, Scalea TM. The prevalence of abnormal results of conventional coagulation tests on admission to a trauma center. Transfusion. 2009;49:34-39.
17. Rugeri L, Levrat A, David JS, Delecroix E, Floccard B, Gros A, Allaouchiche B, Negrier C. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. J Thromb Heamost. 2007;5:289-295.
18. Hagemo JS, Stanworth S, Juffermans NP, Brohi K, Cohen M, Johansson PI, Roislien J, Eken T, Naess P, Gaarder T. Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study. Crit Care. 2014;18:R52.
19. Rourke C, Curry N, Khan S, Taylor R, Raza I, Davenport R, Stanworth S, Brohi K. Fibrinogen levels during trauma hemorrhage, response to replacement therapy, and association with patient outcomes. J Thromb Haemost. 2012;10(7):1342-1351.
20. Inaba K, Karamanos E, Lustenberger T, Schöchl H, Shulman I, Nelson J, Rhee P, Talving P, Lam L, Demetriades D. Impact of fibrinogen levels on outcomes after injury in patients requiring a massive transfusion. J Am Coll Surg. 2013;216(2):290-297.
21. Plotkin A, Wade CE, Jenkins DH, Smith KA, Noe JC, Park MS, Perkins JG, Holcomb JB. A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirement in patients with penetrating injuries. J Trauma. 2008;64(SUPPL. 2):S64-S68.
22. Leemann H, Lustenberger T, Talving P, Kobayashi L, Bukur M, Brenni M, Brüesch M, Spahn DR, Keel MJ. The role of rotation thromboelastometry in early prediction of massive transfusion. J Trauma. 2010;69(6):1403-1408.
23. Schöchl H, Cotton B, Inaba K, Nienaber U, Fischer H, Voelckel W, Solomon C. FIBTEM provides early prediction of massive transfusion in trauma. Crit Care. 2011;15(6):R265.
24. Nystrup KB, Windelov NA, Thomsen AB, Johansson PI. Reduced clot strength upon admission, evaluated by thrombelastography (TEG), in trauma patients is independently associated with increased 30-day mortality. Scand J Trauma Resusc Emerg Med. 2011;19:52.
25. Petzold M, Moore EE, Wohlauer M, Sauaia A, Gonzales E, Banerjee A, Silliman CC. Viscoelastic clot strength predicts coagulation-related mortality within 15 minutes. Surgery. 2012;151(1):48-54.
26. Meyer AS, Meyer MA, Sorensen AM, Rasmussen LS, Hansen MB, Holcomb JB, Cotton BA, Wade CE, Ostrowski SR, Johansson PI. Thrombelastography and rotational thromboelastometry early amplitudes in 182 trauma patients with clinical suspicion of severe injury. J Trauma Acute Care Surg. 2014;76(3):682-690.
27. Kornblith LZ, Kutcher ME, Redick BJ, Calfee CS, Vilardi RF, Cohen MJ. Fibrinogen and platelet contributions to clot formation: implications for trauma resuscitation and thromboprophylaxis. J Trauma Acute Care Surg. 2014;76(2):255-256.
28. Meyer M, Sorensen A, Johansson P. Effect of fibrinogen concentrate on clot strength in trauma: preliminary results of an in vitro study. Scand J Trauma Resusc Emerg Med. 2012;20(Suppl 1):O2.
29. Harr J, Moore E, Ghasabyan A, Chin T, Sauaia A, Banerjee A, Siliman C. Functional fibrinogen assay indicates that fibrinogen is critical in correcting abnormal clot strength following trauma. Shock. 2013;39(1):45-49.
30. Schlimp C, Cadamuro J, Solomon C, Redl H, Schöchl H. The effect of fibrin-ogenconcentrate and factor XIII on thromboelastometry in 33% diluted blood with albumin, gelatine, hydroxyethyl starchor saline invitro. Blood Transfus. 2013;11(4):510-517.
31. Schöchl H, Posch A, Hanke A, Voelckel W, Solomon C. High-dose fibrinogen concentrate for haemostatic therapy of a major trauma patient with recent clopidogrel and aspirin intake. Scand J Clin Lab Invest. 2010;70(6):453-457.
32. Velik-Salchner C, Haas T, Innerhofer P, Streif W, Nussbaumer W, Klingler A, Klima G, Martinowitz U, Fries D. The effect of fibrinogen concentrate on thrombocytopenia. J Thromb Haemost. 2007;5(5):1019-1025.
33. Kozek-Langenecker S, Sorensen B, Hess JR, Spahn DR. Clinical effectiveness of fresh frozen plasma compared with fibrinogen concentrate: a systematic review. Crit Care. 2011;15(5):R239.
34. Aubron C, Reade MC, Fraser JF, Cooper DJ. Efficacy and safety of fibrinogen concentrate in trauma patients - a systematic review. J Crit Care. 2014; 29(3):471.e11-471.e17.
35. Schlimp CJ, Voelckel W, Inaba K, Maegele M, Schöchl H. Impact of fibrinogen concentrate alone or with prothrombin complex concentrate (+/-freshfrozen plasma) on plasma fibrinogen level and fibrin-basedclot strength (FIBTEM) in major trauma: a retrospective study. Scand J Trauma Resusc Emerg Med. 2013;21:74.
36. Fenger-Eriksen C, Lindberg-Larsen M, Christensen AQ, Ingerslev J, Sorensen B. Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br JAnaesth. 2008; 101:769-773.
37. Schöchl H, Nienaber U, Hofer G, Voelkel W, Jambor C, Scharbert G, Kozek-Langenecker S, Solomon C. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)Yguided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.
38. Schöchl H, Nienaber U, Maegele M, Hochleitner G, Primavesi F, Steitz B, Arndt C, Hanke A, Voelckel W, Solomon C. Transfusion in trauma: thromboelastometry-guided coagulation factor concentrate-based therapy versus standard fresh frozen plasma-based therapy. Crit Care. 2011; 15:R83.
39. Nienaber U, Innerhofer P, Westermann I, Schöchl H, Attal R, Breitkopf R, Maegele M. The impact of fresh frozen plasma versus coagulation factor concentrates on morbidity and mortality in trauma-associated haemorrhage and massive transfusion. Injury. 2011;42:697-701.
40. Shaz B, Dente C, Nicolas J, MacLeod JB, Young AN, Easly K, Ling Q, Harris RS, Hillyer CD. Increased number of coagulation products in relationship to red blood cell products transfused improves mortality in trauma patients. Transfusion. 2010;50:493-500.
41. Wafaisade A, Lefering R, Maegele M, Brockamp T, Mutschler M, Lendemans S, Banerjee M, Bouillon B, Probst C; Trauma Registry of DGU. Administration of fibrinogen concentrate in exsanguinating trauma patients is associated with improved survivalat 6 hours but not atdischarge. J Trauma Acute Care Surg. 2013;74(2):387-393.
42. Stinger HK, Spinella PC, Perkins JG, Grathwohl KW, Salinas J, Martini WZ, Hess JR, Dubick MA, Simon CD, Beekly AC, Wolf SE, Wade CE, Holcomb JB. The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital. J Trauma. 2008;64(SUPPL. 2):S79-S85.
43. Morrison JJ, Ross JD, Dubose JJ, Jansen JO, Midwinter MJ, Rasmussen T. Association of cryoprecipitate and tranexamic acid with improved survival following wartime injury: findings from the MATTERs II Study. JAMA Surg. 2013;148(3):218-225.
44. Solomon C, Baryshnikova E, Tripodi A, Schlimp CJ, Schöchl H, Cadamuro J, Winstedt D, Asmis L, Ranucci M. Fibrinogen measurement in cardiac surgery with cardiopulmonary bypass: analysis of repeatability and agreement of Clauss method within and between six different laboratories. Thromb Haemost. 2014;112(1):109-117.
45. Collins PW, Solomon C, Sutor K, Crispin D, Hochleitner G, Rizoli S, Schöchl H, Schreiber M, Ranucci M. Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. Br J Anaesth. 2014;113(4):585-595.
46. Spahn DR, Bouillon B, Cerny V, Coats TJ, Duranteau J, Fernandez-Mondejar E, Filipescu D, Hunt BJ, Komadina R, Nardi G, Neugebauer E, Ozier Y, Riddez L, Schultz A, Vincent JL, Rossaint R. Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care. 2013;17(2):R76.
47. Beyerle A, Nolte MW, Solomon C, Herzog E, Dickneite G. Analysis of the safety and pharmacodynamics of human fibrinogen concentrate in animals. Toxicol Appl Pharmacol. 2014;280(1):70-77.
48. Fenger-Eriksen C, Jensen TM, Kristensen BS, Jensen KM, Tonnesen E, Ingerslev J, Sorensen B. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. J Thromb Haemost. 2009;7:795-802.
49. Karlsson M, Ternström L, Hyllner M, Beghaei F, Flinck A, Skrtic S, Jeppsson A. Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study. Thromb Haemost. 2009;102:137-144.
50. Schöchl H, Voelckel W, Maegele M, Kirchmair L, Schlimp C. Endogenous thrombin potential following hemostatic therapy with 4-factor prothrombin complex concentrate: a 7-day observational study of trauma patients. Crit Care. 2014;18(4):R147.
51. Zentai C, Braunschweig T, Schnabel J, Rose M, Rossaint R, Grottke O. Fibrinogen concentrate does not suppress endogenous fibrinogen synthesis in a 24-hour porcine trauma model. Anesthesiology. 2014;121(4):753-764.
52. Pahlman LI, Mörgelin M, Kasetty G, Olin AI, Schmidtchen A, Herwald H. Antimicrobial activity of fibrinogen and fibrinogen-derived peptides - a novel links between coagulation and innate immunity. Thromb Haemost. 2013;109(5):930-939.
53. ClinicalTrials.gov. REPLACE: Implantable Cardiac Pulse Generator Replacement Registry. Available at: http://clinicaltrials.gov/show/NCT00395447.
54. Fries D, Krismer A, Klingler A, Streif W, Klima G, Wenzel V, Haas T, Innerhofer P. Effect of fibrinogen on reversal of dilutional coagulopathy: a porcine model. Br J Anaesth. 2005;95(2):172-177.
55. Grottke O, Braunschweig T, Henzler D, Coburn M, Tolba R, Rossaint R. Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury. Crit Care. 2010;14(2):R62.
56. Martini J, Maisch S, Pilshofer L, Streif W, Martini W, Fries D. Fibrinogen concentrate in dilutional coagulopathy: a dose study in pigs. Transfusion. 2014;54(1):149-157.
57. Harr JN, Moore EE, Chin TL, Ghasabyan A, Gonzales E, Wohlauer MV, Sauaia A, Banerjee A, Silliman CC. Postinjury hyperfibrinogenemia compromises efficacy of heparin-based venous thromboembolism prophylaxis. Shock. 2014;41(1):33-39.
58. Stanworth SJ, Hunt BJ. The desperate need for good-quality clinical trials to evaluate the optimal source and dose of fibrinogen in managing bleeding. Crit Care. 2011;15:1006.
59. Lunde J, Stensballe J, Wikkelso A, Johansen M, Afshari A. Fibrinogen concentrate for bleeding - a systematic review. Acta Anaesthesiol Scand. 2014;58(9):1061-1074.
60. Davenport R, Brohi K. Fibrinogen depletionintrauma: early, easytoestimate and central to trauma-induced coagulopathy. Crit Care. 2013;17(5):190.
61. ClinicalTrials.gov. Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC). Available at: http://clinicaltrials.gov/show/NCT01475344.